2019
DOI: 10.4093/dmj.2019.0137
|View full text |Cite
|
Sign up to set email alerts
|

2019 Clinical Practice Guidelines for Type 2 Diabetes Mellitus in Korea

Abstract: The Committee of Clinical Practice Guidelines of the Korean Diabetes Association revised and updated the 6th Clinical Practice Guidelines in 2019. Targets of glycemic, blood pressure, and lipid control in type 2 diabetes mellitus (T2DM) were updated. The obese and overweight population is increasing steadily in Korea, and half of the Koreans with diabetes are obese. Evidence-based recommendations for weight-loss therapy for obesity management as treatment for hyperglycemia in T2DM were provided. In addition, e… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
201
0

Year Published

2020
2020
2024
2024

Publication Types

Select...
4
2
1

Relationship

1
6

Authors

Journals

citations
Cited by 196 publications
(201 citation statements)
references
References 31 publications
0
201
0
Order By: Relevance
“…There was a de nite increase of continuity in age group 40-59, compared to other age groups. Continuity was distinctively lower in young age (20)(21)(22)(23)(24)(25)(26)(27)(28)(29)(30)(31)(32)(33)(34)(35)(36)(37)(38)(39), which can partly be explained by mild severity, less complication, and more frequent residential migration of the group. However, current phenomenon can pose an impending threat to the working population since legacy effect of diabetes has been recently reported 16 .…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…There was a de nite increase of continuity in age group 40-59, compared to other age groups. Continuity was distinctively lower in young age (20)(21)(22)(23)(24)(25)(26)(27)(28)(29)(30)(31)(32)(33)(34)(35)(36)(37)(38)(39), which can partly be explained by mild severity, less complication, and more frequent residential migration of the group. However, current phenomenon can pose an impending threat to the working population since legacy effect of diabetes has been recently reported 16 .…”
Section: Discussionmentioning
confidence: 99%
“…This conveys the large disparity between supply and demand of medical resources in Korea. 2019 American Diabetes Association guideline recommends that diabetes patients should meet their primary care givers every 2 to 3 months 2,25 . Moreover, prevalence of diabetes is closely related to residential location 26 , which implies local physicians can manage their patients in a more customized, communicative manner.…”
Section: Discussionmentioning
confidence: 99%
“…The Korean Ministry of Food and Drug Safety continues to contraindicate the use of metformin for patients with T2DM and CKD stage 3b (creatinine clearance < 45 mL/ min or an eGFR < 45 mL/min/1.73 m 2 ). However, in 2019, the KDA revised its recommendations as follows [22]: Metformin is contraindicated in patients with an eGFR < 30 mL/min/1.73 m 2 ; metformin can be used cautiously in patients with an eGFR between 30 and 45 mL/min/1.73 m 2 .…”
Section: Recent Recommendations On the Use Of Metformin In Chronic Kimentioning
confidence: 99%
“…In 2019, the KDA revised its recommendation that patients with an eGFR < 60 mL/min/1.73 m 2 should discontinue metformin on the day of the procedure for up to 48 hours, and reinstituted metformin therapy if renal function has not declined following the procedure [22].…”
Section: Recent Recommendations Regarding Metformin Discontinu-ation mentioning
confidence: 99%
“…If the initial HbA1c level is greater than or equal to 7.5% or the HbA1c goal is not achieved after 3 months of initiating monotherapy, dual or triple combination therapy can be considered using DPP-4i, sodium-glucose cotransporter-2 inhibitors (SGLT2i), thiazolidinediones, glucagon-like peptide 1 receptor agonists (GLP-1 RAs), SUs, glinides, a-glucosidase inhibitors, and insulin, according to patient circumstances. 10 The general recommendations have not changed from those in the 2017 and 2015 KDA guidelines. Despite the availability of newer agents, such as SGLT2i and GLP-1 RAs, SUs are still widely utilized.…”
mentioning
confidence: 99%